# Novocuff, Inc.

> Novocuff, Inc. is a clinical-stage maternal health medical device company based in Mountain View, California, building the Novocuff Cervical Control System (CCS) - a device designed to stabilize and close the cervix, retain amniotic fluid, and extend pregnancy in cases of preterm prelabor rupture of membranes (PPROM) and cervical shortening. Founded in 2021 by Amelia Degenkolb and Donald Lee, the company raised an oversubscribed $26M Series A in 2024 (about $28M total) to fund its U.S. multicenter pivotal RETAIN trial, for which it secured FDA IDE approval in September 2025.

- **Founded:** 2021
- **Headquarters:** Mountain View, California, United States
- **Founders:** Amelia Degenkolb (Co-Founder & CEO), Donald Lee (Co-Founder & COO)
- **Team size:** Approximately 11 employees
- **Products:** Novocuff Cervical Control System (CCS)
- **Notable:** Raised an oversubscribed $26M Series A in July 2024 (~$28M total funding across 3 rounds)., Secured FDA IDE approval for the pivotal RETAIN study in September 2025., Recruited co-principal investigators from University of Virginia and Brown University for its pivotal trial.

## Products & services

- **Novocuff Cervical Control System (CCS)** — An investigational medical device designed to stabilize and close the cervix, retain amniotic fluid, and maintain cervical length in order to extend gestation in singleton pregnancies complicated by PPROM (as early as 24 weeks) and cervical shortening. Currently limited to investigational use under U.S. law.

## Achievements

- Raised an oversubscribed $26M Series A in July 2024 (~$28M total funding across 3 rounds).
- Secured FDA IDE approval for the pivotal RETAIN study in September 2025.
- Recruited co-principal investigators from University of Virginia and Brown University for its pivotal trial.
- Selected as a company in residence at Fogarty Innovation.
- Built a strategic cap table spanning AXA IM Alts, Laerdal, Laborie, RH Capital, Avestria Ventures, and March of Dimes.

## Latest updates

- **2025-09** — Announced FDA IDE approval for the RETAIN study, a randomized, multicenter pivotal trial enrolling up to 272 participants to evaluate the Cervical Control System for PPROM beginning at 24 weeks.
- **2024-07** — Closed an oversubscribed $26M Series A led by AXA IM Alts to fund team expansion, a U.S. multicenter pivotal trial, and early commercialization.

## Links

- Website: https://novocuff.com
- LinkedIn: https://www.linkedin.com/company/novocuff-inc
- Instagram: https://www.instagram.com/novocuff

---

Profile page: https://yespress.io/novocuff-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13